Home › Funds › BML Capital Management, LLC › CNTB

BML Capital Management, LLC position in CNTB

CONNECT BIOPHARMA HLDGS LTD · Health Care

BML Capital Management, LLC reported holding 3,864,400 shares of CNTB (CONNECT BIOPHARMA HLDGS LTD) in its Q3 2026 13F filing — a position valued at US$4.3M, representing 2.27% of its reported portfolio and ranking #12 among its reported holdings. BML Capital Management, LLC has disclosed CNTB holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)3.86M sh
Reported value held$4.25M
Portfolio Weight2.27%
First reportedQ4 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BML Capital Management, LLC's CNTB position evolved

BML Capital Management, LLC first disclosed a stake in CNTB in Q4 2023 at 2,061,438 shares (US$2.4M). The position peaked in Q3 2026 at 3,864,400 shares, worth US$4.3M. Across 12 filings, BML Capital Management, LLC increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 3,864,400 shares valued at US$4.3M — an increase of 3,291,113 shares quarter over quarter.. Notable position changes include a 68% trim in Q4 2025 (shares fell 7% over the following quarter), a 40% increase in Q2 2026 (shares fell 54% over the following quarter), a 574% increase in Q3 2026 (shares fell 37% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 2.06M $2.43M New
Q1 2024 2.06M $3.59M Hold
Q2 2024 2.04M $3.11M Reduce
Q3 2024 2.09M $3.01M Add
Q4 2024 2.09M $2.89M Hold
Q1 2025 2.09M $1.15M Hold
Q2 2025 1.82M $1.79M Reduce
Q3 2025 1.27M $1.91M Reduce
Q4 2025 408.89K $1.15M Reduce
Q1 2026 408.89K $1.07M Hold
Q2 2026 573.29K $1.36M Add
Q3 2026 3.86M $4.25M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CNTB and 13F data

CNTB (CONNECT BIOPHARMA HLDGS LTD) is a Health Care company. 65 other funds we track also report a position in CNTB — the largest reported positions include Ikarian Capital, LLC (US$10.8M), Richmond Brothers, Inc. (US$1.3M), Stonepine Capital Management, LLC (US$867K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CNTB

All CNTB fund holders →

FAQ

How long has BML Capital Management, LLC held CNTB?

BML Capital Management, LLC has disclosed CNTB holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is BML Capital Management, LLC's current position in CNTB?

As of Q3 2026, BML Capital Management, LLC holds 3.86M shares of CNTB (CONNECT BIOPHARMA HLDGS LTD), valued at $4.25M, representing 2.27% of its reported portfolio and ranking #12.

Has BML Capital Management, LLC been buying or selling CNTB?

In the latest 13F filing (Q3 2026), BML Capital Management, LLC increased its position in CNTB. The position peaked in Q3 2026 at 3.86M shares.

Which other funds hold CNTB?

Other major institutional holders of CNTB include Ikarian Capital, LLC, Richmond Brothers, Inc., Stonepine Capital Management, LLC, among 65 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.